LEXINGTON, Mass.--(BUSINESS WIRE)--GI Dynamics, a medical device company pioneering the development of new approaches to treat obesity and type 2 diabetes, announced today a paper appearing in the advance online publication of the journal Obesity, which demonstrates that implantation of an innovative endoluminal sleeve mimics key, beneficial effects of Roux-en-Y gastric bypass (RYGB) surgery, inducing substantial weight loss and improved metabolic function in rats with diet-induced obesity. The dramatic effects of the removable device on blood glucose levels in this animal model suggest an important role for the duodenum (the first part of the small intestine) and jejunum (the central part of the small intestine) in the regulation of this metabolic function. GI Dynamics is developing an endoluminal sleeve, known as the EndoBarrier™ Gastrointestinal Liner, and is currently in late-stage clinical trials.
